Spdmb

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Spdmb
• 英文别名: (2,5-dioxopyrrolidin-1-yl) 3-methyl-3-(pyridin-2-yldisulfanyl)butanoate
• 化学式: C₁₄H₁₆N₂O₄S₂
• 分子量: 340.4
• InChiKey: KUSWWWVFHGSSGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  127
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• NUCLEOSIDE ANALOGUE, PREPARATION METHOD AND APPLICATION
  申请人：GENEMIND BIOSCIENCES COMPANY LIMITED

  公开号：US20200283467A1

  公开（公告）日：2020-09-10

  Nucleoside or nucleotide analog compounds having the structure shown below, a method for preparing them, and applications in nucleic acid sequencing are disclosed. The compounds have formula (I): wherein L 1 , L 2 , and L 3 are each independently a covalent bond or a covalently linked group; B is a base or a base derivative selected from purines, pyrimidines, or analogs thereof; R 1 is —OH, a phosphate group, or a nucleotide; R 2 as H or a cleavable group; R 3 is a detectable group or a targeting group; R 5 is an inhibitory group; R 4 is H, —NH 2 , or —OR 6 , wherein R 6 is H or a cleavable group; and C is a cleavable group or a cleavable bond.

  揭示了具有下面所示结构的核苷酸或核苷酸类似化合物，其制备方法以及在核酸测序中的应用。这些化合物具有公式（I）：其中L1、L2和L3分别独立地是共价键或共价连接的基团；B是从嘌呤、嘧啶或其类似物中选择的碱基或碱基衍生物；R1是—OH、磷酸基团或核苷酸；R2是H或可裂解基团；R3是可检测基团或靶向基团；R5是抑制基团；R4是H、—NH2或—OR6，其中R6是H或可裂解基团；C是可裂解基团或可裂解键。
• Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
  申请人：Oregon Health & Science University

  公开号：US11224573B2

  公开（公告）日：2022-01-18

  Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics.

  本文公开了包括递送颗粒、至少一种有丝分裂激酶抑制剂和至少一种免疫检查点抑制剂的治疗构建物。还公开了包括有丝分裂激酶抑制剂、免疫检查点抑制剂和化学连接体的治疗构建物。这些治疗构建物通过治疗和免疫效应导致癌症死亡，并在正反馈循环中促进更多治疗药物靶向输送到存活的癌细胞。它们提高了游离药物的治疗指数，可在肿瘤内或全身使用。这种策略可治疗多种类型的癌症，尤其适用于没有明显受体的癌症，可为癌症靶向输送原本有毒的治疗药物。
• Nucleoside analogue, preparation method and application
  申请人：GENEMIND BIOSCIENCES COMPANY LIMITED

  公开号：US11512106B2

  公开（公告）日：2022-11-29

  Nucleoside or nucleotide analog compounds having the structure shown below, a method for preparing them, and applications in nucleic acid sequencing are disclosed. The compounds have formula (I): wherein L 1 , L 2 , and L 3 are each independently a covalent bond or a covalently linked group; B is a base or a base derivative selected from purines, pyrimidines, or analogs thereof; R 1 is —OH, a phosphate group, or a nucleotide; R 2 as H or a cleavable group; R 3 is a detectable group or a targeting group; R 5 is an inhibitory group; R 4 is H, —NH 2 , or —OR 6 , wherein R 6 is H or a cleavable group; and C is a cleavable group or a cleavable bond.

  本发明公开了具有下图所示结构的核苷或核苷酸类似物化合物、其制备方法以及在核酸测序中的应用。这些化合物具有式（I）： 其中 L 1 , L 2 和 L 3 各自独立地为共价键或共价连接基团； B 是碱或碱衍生物，选自嘌呤、嘧啶或其类似物； R 1 是-OH、磷酸基团或核苷酸；R 2 为 H 或可裂解基团；R 3 是可检测基团或靶向基团；R 5 是抑制基团 4 是 H、-NH 2 或-OR 6 其中 R 6 是 H 或可裂解基团；C 是可裂解基团或可裂解键。
• THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR
  申请人：Oregon Health & Science University

  公开号：EP3996750A1

  公开（公告）日：2022-05-18
• [EN] THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR<br/>[FR] CONSTRUCTIONS THÉRAPEUTIQUES POUR LA CO-ADMINISTRATION D'UN INHIBITEUR DE LA KINASE MITOTIQUE ET D'UN INHIBITEUR DES POINTS DE CONTRÔLE IMMUNITAIRE
  申请人：UNIV OREGON HEALTH & SCIENCE

  公开号：WO2021011501A1

  公开（公告）日：2021-01-21

  Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer- targeted delivery of otherwise toxic therapeutics.